Npt2b deletion attenuates hyperphosphatemia associated with CKD.

Area of Science:

• Nephrology
• Endocrinology
• Bone Metabolism

Background:

• Cardiovascular events and mortality in chronic kidney disease (CKD) correlate with serum phosphate levels.
• The Npt2b transporter is crucial for phosphate homeostasis in healthy kidneys, but its role in CKD-associated hyperphosphatemia is unclear.

Purpose of the Study:

• To investigate the role of the Npt2b transporter in CKD-induced hyperphosphatemia and associated bone disease.
• To evaluate the therapeutic potential of targeting Npt2b in conjunction with phosphate binders.

Main Methods:

• Adenine-induced uremia in Npt2b-deficient and wild-type mice.
• Administration of sevelamer carbonate to Npt2b-deficient mice.
• Assessment of serum phosphate, FGF23 levels, and bone histomorphometry.

Main Results:

• Npt2b-deficient uremic mice exhibited lower serum phosphate and FGF23 levels compared to wild-type uremic mice.
• Sevelamer carbonate treatment further reduced serum phosphate in Npt2b-deficient mice.
• Sevelamer treatment decreased osteoclast number and mineral apposition rate in Npt2b-deficient mice, but not in wild-type mice.

Conclusions:

• Npt2b plays a significant role in regulating phosphate levels during CKD.
• Targeting Npt2b, alongside dietary phosphate binders, may offer a novel therapeutic strategy for managing hyperphosphatemia and renal osteodystrophy in CKD.